VIBECOTAMAB
UNII JD56EJA59S

Substance Identification & Data

This profile provides standardized clinical and technical data for Vibecotamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) JD56EJA59S.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2138442-13-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

JD56EJA59S

CAS Registry Number

2138442-13-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VIBECOTAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C127120

National Cancer Institute reference terminology for clinical and research data.

INN ID

11021

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-137

Identifier assigned by the United States Adopted Names Council.

Substance Type

VIBECOTAMAB

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vibecotamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VIBECOTAMAB

Common Names & Synonyms

ANTI-CD123 X ANTI-CD3 BISPECIFIC ANTIBODY XMAB14045

VIBECOTAMAB [USAN]

Vibecotamab [WHO-DD]

vibecotamab [INN]

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN CD3 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB14045 .GAMMA.1-CHAIN), (265->229'),(268->232')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1, ANTI-(HUMAN CD123 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB14045 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB14045 .KAPPA.-CHAIN

SYS

IMMUNOGLOBULIN HALF-G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS IL3RA (INTERLEUKIN 3 RECEPTOR SUBUNIT ALPHA, INTERLEUKIN 3 RECEPTOR, ALPHA (LOW AFFINITY), CD123) AND HOMO SAPIENS CD3 EPSILON (CD3E, LEU-4)), MONOCLONAL ANTIBODY, BISPECIFICGAMMA1 HEAVY CHAIN ANTI-IL3RA (1-449) (VH (MUS MUSCULUS IGHV1-26*01(83.7%)-(IGHD)-IGHJ3*01(93.3%)/HOMO SAPIENS IGHV1-46*01 (78.6%)-(IGHD)-IGHJ6*01 (90.9%)) (8.8.13) (1-120)-HOMO SAPIENS IGHG1*03V (CH1 N114>D (211), R120>K (217) (121-218), HINGE 1-15 (219-233), CH2 E1.4>P (236), L1.2>V (237), G1.1>A (238), S29>K (269), Q84.2>E (297) (234-342), CH3 E12 (358), M14 (360), L24>D (370), K26>S (372), N44>D (386), Q97>E (420), N100>D (423) (343-447), CHS (448-449)) (121-449)), (223-220')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI IL3RA (1'-220') (VKAPPA (HOMO SAPIENS IGKV4-1*01 (89.1%)-IGKJ2*01 (91.7%)) (12.3.9) (1'-113')-HOMO SAPIENS IGKC*01 (100%) A45.1 (159), V101 (197) (114'-220'))HEAVY CHAIN SCFV-H-CH2-CH3, ANTI-CD3E (1-485) (VH (HOMO SAPIENS IGHV3-73*01 (87.0%)-(IGHD)-IGHJ6*01 (90.9%)) (8.10.16) (1-125)-20-MER LINKER (126-145)-V-LAMBDA (MUS MUSCULUS IGLV1*01 (80.6%)-IGLJ1*01 (100%)/HOMO SAPIENS IGLV7-46*01 (76.8%)-IGHJ3*02 (100%)) (9.3.9) (146-254)-IGHG1*03 (HINGE 1-15 C5>S (259) (255-269)-CH2 E1.4>P (272), L1.2>V (273), G1.1>A (274), S29>K (305) (270-378),CH3 E12 (394), E13>Q (395), M14 (396), S20>K (402)(379-483), CHS (484-485)) (1-485))DIMER (229-265'':232-268'')-BISDISULFIDE

SYS